Medarex Strikes Partnership With Compugen For Oncology and Autoimmune Drug Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will share development and commercialization costs associated with products resulting from the agreement.
You may also be interested in...
Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.
Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.
Medarex Partners With GenPat77 To Develop Human Therapeutic Antibodies
Agreement adds another player to Medarex’ roster of development partners, which include Bristol-Myers Squibb and J&J.